GlassScriptPhysician profile
Dean E Firschein
NPI 1336139765
$4,159.82
in general payments reported to CMS, 2019-2025
25 companies · $1,570 in 2025
The $1,570 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $149 · 2021: $233 · 2022: $269 · 2023: $279 · 2024: $987 · 2025: $1,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,803 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,802.70 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $682.42 | 2019-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $568.30 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $531.26 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $309.43 | 2020-2025 | Takhzyro, Cuvitru |
| Novartis Pharmaceuticals Corporation | $282.76 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $282.62 | 2019-2025 | Dupixent |
| Pfizer INC. | $259.85 | 2019-2025 | |
| Amgen INC. | $224.12 | 2024-2025 | Tezspire |
| Grifols USA, LLC | $209.81 | 2019-2025 | Xembify |
| Csl Behring | $117.36 | 2019-2025 | Hizentra, Andembry |
| Ars Pharmaceuticals Operations, INC. | $81.00 | 2025 | Neffy |
| Pharming Healthcare, INC. | $76.70 | 2024-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $70.20 | 2021 | |
| Optinose US, INC. | $64.93 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.86 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $56.44 | 2024-2025 | Ayvakit |
| Genentech USA, INC. | $44.31 | 2020-2025 | Xolair |
| Kaleo, INC. | $43.67 | 2019-2020 | |
| Kedrion Biopharma, INC. | $41.98 | 2024 | Kedrab, Albuked, Rhogam Ultra-Filtered Plus |
| Alk-Abello, INC | $35.97 | 2019-2020 | |
| Phadia US INC. | $34.62 | 2019 | |
| Organon LLC | $27.32 | 2025 | |
| Octapharma USA, INC. | $18.51 | 2024 | Cutaquig |
| Galderma Laboratories, L.P. | $16.00 | 2025 | Nemluvio |
| Circassia INC. | $15.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Firschein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.